These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 36142174)

  • 1. Editorial for the Special Issue "New Drugs for Breast Cancer Treatment".
    Acconcia F
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mini review: The FDA-approved prescription drugs that target the MAPK signaling pathway in women with breast cancer.
    Khojasteh Poor F; Keivan M; Ramazii M; Ghaedrahmati F; Anbiyaiee A; Panahandeh S; Khoshnam SE; Farzaneh M
    Breast Dis; 2021; 40(2):51-62. PubMed ID: 33896802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer: An insight into its inflammatory, molecular, pathological and targeted facets with update on investigational drugs.
    Harwansh RK; Deshmukh R
    Crit Rev Oncol Hematol; 2020 Oct; 154():103070. PubMed ID: 32871325
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Hub Genes to Regulate Breast Cancer Spinal Metastases by Bioinformatics Analyses.
    He Y; Cao Y; Wang X; Jisiguleng W; Tao M; Liu J; Wang F; Chao L; Wang W; Li P; Fu H; Xing W; Zhu Z; Huan Y; Yuan H
    Comput Math Methods Med; 2021; 2021():5548918. PubMed ID: 34055036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting breast cancer drug response using a multiple-layer cell line drug response network model.
    Huang S; Hu P; Lakowski TM
    BMC Cancer; 2021 May; 21(1):648. PubMed ID: 34059012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent Development in Indole Derivatives as Anticancer Agents for Breast Cancer.
    Kaur K; Jaitak V
    Anticancer Agents Med Chem; 2019; 19(8):962-983. PubMed ID: 30864529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Trastuzumab for Neoadjuvant Therapy of HER2+ Breast Cancer - 5-Years of Experience in a Single Clinic.
    Zuazana B; Luboš P; Renata C
    Klin Onkol; 2018; 31(3):191-199. PubMed ID: 30441972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Editorial Special Issue Section on Young Women and Breast Cancer. Monographic issue.
    Cano A
    Eur J Obstet Gynecol Reprod Biol; 2018 Nov; 230():203. PubMed ID: 30181025
    [No Abstract]   [Full Text] [Related]  

  • 9. Ursolic acid a promising candidate in the therapeutics of breast cancer: Current status and future implications.
    Iqbal J; Abbasi BA; Ahmad R; Mahmood T; Kanwal S; Ali B; Khalil AT; Shah SA; Alam MM; Badshah H
    Biomed Pharmacother; 2018 Dec; 108():752-756. PubMed ID: 30248543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced Fit Docking and Automated QSAR Studies Reveal the ER-α Inhibitory Activity of Cannabis sativa in Breast Cancer.
    Kikiowo B; Ogunleye AJ; Iwaloye O; Ijatuyi TT; Adelakun NS; Alashe WO
    Recent Pat Anticancer Drug Discov; 2021; 16(2):273-284. PubMed ID: 33563181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanding the Biotherapeutics Realm via miR-34a: "Potent Clever Little" Agent in Breast Cancer Therapy.
    Mohammady M; Ghetmiri SI; Baharizade M; Morowvat MH; Torabi S
    Curr Pharm Biotechnol; 2019; 20(8):665-673. PubMed ID: 31244419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs repurposed: An advanced step towards the treatment of breast cancer and associated challenges.
    Malik JA; Ahmed S; Jan B; Bender O; Al Hagbani T; Alqarni A; Anwar S
    Biomed Pharmacother; 2022 Jan; 145():112375. PubMed ID: 34863612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence.
    Abbaspour M; Akbari V
    Expert Rev Vaccines; 2022 Mar; 21(3):337-353. PubMed ID: 34932427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis.
    Asghari A; Wall K; Gill M; Vecchio ND; Allahbakhsh F; Wu J; Deng N; Zheng WJ; Wu H; Umetani M; Maroufy V
    Oncotarget; 2022; 13():600-613. PubMed ID: 35401937
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulated lytic cell death in breast cancer.
    Liu M; Wang L; Xia X; Wu Y; Zhu C; Duan M; Wei X; Hu J; Lei L
    Cell Biol Int; 2022 Jan; 46(1):12-33. PubMed ID: 34549863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial peptides as potential therapeutics for breast cancer.
    Aghamiri S; Zandsalimi F; Raee P; Abdollahifar MA; Tan SC; Low TY; Najafi S; Ashrafizadeh M; Zarrabi A; Ghanbarian H; Bandehpour M
    Pharmacol Res; 2021 Sep; 171():105777. PubMed ID: 34298112
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapy strategies in the management of breast cancer.
    Yardim-Akaydin S; Karahalil B; Baytas SN
    Drug Discov Today; 2022 Jun; 27(6):1755-1762. PubMed ID: 35337961
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Silencing ARHGAP9 correlates with the risk of breast cancer and inhibits the proliferation, migration, and invasion of breast cancer.
    Wang T; Ha M
    J Cell Biochem; 2018 Sep; 119(9):7747-7756. PubMed ID: 29905031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous downregulation of miR-21 and miR-155 through oleuropein for breast cancer prevention and therapy.
    Abtin M; Alivand MR; Khaniani MS; Bastami M; Zaeifizadeh M; Derakhshan SM
    J Cell Biochem; 2018 Sep; 119(9):7151-7165. PubMed ID: 29905007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. NUF2 as an anticancer therapeutic target and prognostic factor in breast cancer.
    Lv S; Xu W; Zhang Y; Zhang J; Dong X
    Int J Oncol; 2020 Dec; 57(6):1358-1367. PubMed ID: 33173994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.